Skip to main content
OpenTrials

Clinical trial condition

Flaviviridae Infections

Explore clinical trials studying Flaviviridae Infections. Study availability and eligibility vary by location and protocol.

2,144 public trials 77 recruiting studies
Refine in advanced search Browse all conditions

Flaviviridae Infections trial results

Completed

Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)

NCT01399619

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1220.19.0045 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1220.19.0007 Boehringer Ingelheim Investigational Site Palm Springs, California, United States
  • 1220.19.0031 Boehringer Ingelheim Investigational Site San Francisco, California, United States
  • 1220.19.0005 Boehringer Ingelheim Investigational Site Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details
Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

NCT01358864

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1220.7.0091 Boehringer Ingelheim Investigational Site North Little Rock, Arkansas, United States
  • 1220.7.0082 Boehringer Ingelheim Investigational Site Englewood, Colorado, United States
  • 1220.7.0095 Boehringer Ingelheim Investigational Site Palm Harbor, Florida, United States
  • 1220.7.0039 Boehringer Ingelheim Investigational Site Columbus, Georgia, United States
View all 116 locations
View Trial Details
Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

NCT02753699

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Novartis Investigative Site La Jolla, California, United States
  • Novartis Investigative Site San Diego, California, United States
  • Novartis Investigative Site Ventura, California, United States
  • Novartis Investigative Site Bradenton, Florida, United States
View all 119 locations
View Trial Details
Completed

Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment

NCT01183169

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Novartis Investigative Site San Diego, California, United States
  • Novartis Investigative Site San Diego, California, United States
  • Novartis Investigative Site Ventura, California, United States
  • Novartis Investigative Site Bradenton, Florida, United States
View all 75 locations
View Trial Details

Related conditions